Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule

S M Lichtman; A Mittelman; D R Budman; C A Puccio; H G Chun; S L Allen; T Ahmed; Z A Arlin

doi:10.3109/10428199109064880

Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule

Leuk Lymphoma. 1991;6(1):61-3. doi: 10.3109/10428199109064880.

Authors

S M Lichtman¹, A Mittelman², D R Budman¹, C A Puccio², H G Chun^{3

4}, S L Allen¹, T Ahmed², Z A Arlin²

Affiliations

¹ a From: Don Monti Division of Oncology, Department of Medicine, Department of Medicine, North Shore University Hospital-Cornell University Medical College, Manhasset, NY, Cornell University Medical College, New York.
² b Division of Neoplastic Diseases, Department of Medicine, New York Medical College, Valhalla, New York, USA.
³ c Investigational Drug Branch, Cancer Therapy Evaluation Program Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA.
⁴ d Division of Neoplastic Diseases, New York Medical College, Valhalla, New York.

PMID: 27457577
DOI: 10.3109/10428199109064880

Abstract

A phase II trial of fludarabine phosphate using a bolus and continuous infusion regimen in previously treated multiple myeloma was performed. No responses were observed in eleven patients. There was no significant non-hematologic toxicity noted. Fludarabine phosphate is inactive in multiple myeloma using this schedule.

Keywords: fludarabine phosphate; multiple myeloma.